Innate Immune Defenses Against Filoviruses.
Innate Immune Defenses Against Filoviruses.
批准号:
7964676
负责人:
RONALD N HARTY
金额:
$19.99万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-06-01 至 2012-05-31
关键词:
Antiviral AgentsBioterrorismCell SeparationDendritic CellsDiseaseDisease ProgressionEbola virusEventFilovirusGenesGoalsHumanImmuneImmune responseImmune systemInfectionInfection preventionInflammatoryInterferonsLeadLearningMediatingMediator of activation proteinParamyxovirusPathogenesisPathway interactionsPlayProteinsRNA VirusesRhabdoviridaeRoleSeveritiesSignal TransductionStagingTLR4 geneTherapeuticUbiquitinationVaccinesViralVirusVirus AssemblyVirus ReplicationVirus-like particlecytokinemacrophagemonocytepathogenpublic health relevanceresponsetherapeutic vaccineubiquitin ligaseubiquitin-protein ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Negative-sense RNA viruses including filoviruses, rhabdoviruses and paramyxoviruses are the cause of a multitude of serious diseases in humans worldwide. Assembly and budding are important late events in the replication cycles of these viruses. While much has been learned regarding these dynamic and multifaceted stages of replication, host pathways that modulate virus assembly/budding continue to be identified. Assembly/budding of filoviruses and virus-like particles (VLPs) is driven largely by the matrix protein, VP40. We and others have shown that Late budding domains (L-domains) within VP40 are important for efficient budding, as they mediate interactions with host proteins (e.g. Nedd4 ubiquitin ligase) to facilitate virus-cell separation. Notably, it is becoming clear that host innate immune responses result in the induction of a myriad of proteins that modulate virus replication, budding, and pathogenesis. The innate immune response represents the first critical line of defense against viral pathogens, and importantly, ebolavirus and marburgvirus target key regulators of this response including macrophages/monocytes and dendritic cells. A better understanding of host innate immune interactions and responses to filoviruses will be crucial for developing therapeutics and vaccines to treat and prevent infection. Toward this end, we demonstrated recently that expression of interferon stimulated gene ISG15 resulted in inhibition of VP40 ubiquitination and subsequent egress of VP40 VLPs. Although identification of this previously undescribed mechanism of antiviral activity for ISG15 against ebolavirus was an important first step, our understanding of how ISG15 and associated ISGylation factors inhibit budding of ebolavirus and possibly marburgvirus remains incomplete. The overarching goals of this proposal are to determine whether Ebola VLPs can induce expression of IFN-regulated Herc5 E3 ligase through a TLR4-dependent pathway, whether Herc5 E3 ligase contributes to ISGylation of target proteins (host or viral) resulting in inhibition of ebolavirus budding, and whether host ubiquitination and ISGylation pathways play a competing role in modulating budding of marburgvirus VLPs. We believe that these studies will have a major impact on our understanding of the interplay between filovirus proteins and components of the innate immune system leading to modulation of virus egress and likely disease progression and severity. In addition, our findings will also impact our understanding of how manipulation of host immune response mediators may have therapeutic benefit, and may help to optimize immunological responses to potential vaccines (e.g. ebolavirus or marburgvirus VLPs) and/or vaccine components (e.g. ebolavirus or marburgvirus GP and VP40).
PUBLIC HEALTH RELEVANCE: The filoviruses are deadly human pathogens and potential agents of bioterrorism for which no vaccines, nor antivirals exist. The innate immune system represents a first critical line of defense against these viral pathogens. A better understanding of how the host innate immune system recognizes, responds, and defends against filovirus infection will be critical for developing effective therapeutics and vaccines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of Host Filamin Proteins in Regulating Filovirus Entry and Egress
-
批准号:10644499
-
项目类别:
-
资助金额:$26.83万
-
财政年份:2023
-
负责人:RONALD N HARTY
-
依托单位:
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
-
批准号:10688262
-
项目类别:
-
资助金额:$29.24万
-
财政年份:2022
-
负责人:RONALD N HARTY
-
依托单位:
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
-
批准号:10545109
-
项目类别:
-
资助金额:$30.65万
-
财政年份:2022
-
负责人:RONALD N HARTY
-
依托单位:
Role of Host Angiomotin as a Central Regulator of Filovirus Egress and Dissemination
-
批准号:10380684
-
项目类别:
-
资助金额:$22.53万
-
财政年份:2021
-
负责人:RONALD N HARTY
-
依托单位:
Role of Host Angiomotin as a Central Regulator of Filovirus Egress and Dissemination
-
批准号:10217843
-
项目类别:
-
资助金额:$28.58万
-
财政年份:2021
-
负责人:RONALD N HARTY
-
依托单位:
Modular Domains of Host Proteins Regulate Filovirus Maturation
-
批准号:9517218
-
项目类别:
-
资助金额:$24.64万
-
财政年份:2018
-
负责人:RONALD N HARTY
-
依托单位:
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
-
批准号:10257889
-
项目类别:
-
资助金额:$101.7万
-
财政年份:2018
-
负责人:RONALD N HARTY
-
依托单位:
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
-
批准号:10368115
-
项目类别:
-
资助金额:$101.54万
-
财政年份:2018
-
负责人:RONALD N HARTY
-
依托单位:
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
-
批准号:10599837
-
项目类别:
-
资助金额:$101.29万
-
财政年份:2018
-
负责人:RONALD N HARTY
-
依托单位:
DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS AGAINST RNA VIRUSES
-
批准号:8903846
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2015
-
负责人:RONALD N HARTY
-
依托单位:
Innate Immune Regulation of Intracellular Pathways Involved in Filovirus Budding
-
批准号:8635498
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2013
-
负责人:RONALD N HARTY
-
依托单位:
Host-Oriented Therapeutics Targeting Filovirus Budding.
-
批准号:8853616
-
项目类别:
-
资助金额:$46.66万
-
财政年份:2012
-
负责人:RONALD N HARTY
-
依托单位:
Host-Oriented Therapeutics Targeting Filovirus Budding.
-
批准号:8490299
-
项目类别:
-
资助金额:$22.27万
-
财政年份:2012
-
负责人:RONALD N HARTY
-
依托单位:
Host-Oriented Therapeutics Targeting Filovirus Budding.
-
批准号:8389432
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:RONALD N HARTY
-
依托单位:
Host-Oriented Therapeutics Targeting Filovirus Budding.
-
批准号:9088302
-
项目类别:
-
资助金额:$47.28万
-
财政年份:2012
-
负责人:RONALD N HARTY
-
依托单位:
Innate Immune Defenses Against Filoviruses.
-
批准号:8076883
-
项目类别:
-
资助金额:$23.76万
-
财政年份:2010
-
负责人:RONALD N HARTY
-
依托单位:
Role of ISG15 in Inhibition of Ebola Virus Budding
-
批准号:7927824
-
项目类别:
-
资助金额:$18.51万
-
财政年份:2007
-
负责人:RONALD N HARTY
-
依托单位:
Packaging of Ebola Virus RNA into Budding VLPs
-
批准号:7339650
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2007
-
负责人:RONALD N HARTY
-
依托单位:
Role of ISG15 in Inhibition of Ebola Virus Budding
-
批准号:7391373
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2007
-
负责人:RONALD N HARTY
-
依托单位:
Packaging of Ebola Virus RNA into Budding VLPs
-
批准号:7176652
-
项目类别:
-
资助金额:$23.59万
-
财政年份:2007
-
负责人:RONALD N HARTY
-
依托单位:
海外基金